Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 15/20 | 0.46 |
| ▸ | TOP1 | P11387 | 4/20 | 0.46 |
| ▸ | TOP2B | Q02880 | 10/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728645 | 0.94 | TOP2A (0.48) | TOP2ATOP1TOP2BALDH1A1POLB | |
| SCHEMBL19728770 | 0.91 | ALDH1A1 (0.49) | TOP2ATOP1TOP2BALDH1A1POLB | |
| SCHEMBL20912606 | 0.91 | TOP2A (0.48) | TOP2ATOP1TOP2BALDH1A1POLB | |
| SCHEMBL19729348 | 0.88 | STAT3 (0.40) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19728735 | 0.87 | STAT3 (0.38) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19728717 | 0.87 | STAT3 (0.38) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19728792 | 0.85 | KDM4E (0.47) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19728789 | 0.85 | KDM4E (0.47) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19729066 | 0.85 | STAT3 (0.38) | TOP2ATOP1TOP2BALDH1A1 | |
| SCHEMBL19729059 | 0.85 | STAT3 (0.47) | TOP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017217441-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | 湧永製薬株式会社 | 2017-12-21 | — | — | WO | disclosed |